Search Results for "Fungal"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Fungal. Results 21 to 30 of 67 total matches.

Caspofungin (Cancidas) For Aspergillosis

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001  (Issue 1108)
in other fungal infections, particularly deep Candida infections, and whether it would be more effective ...
Caspofungin acetate(Cancidas) is the first of a new class of antifungals, the echinocandins. It has been approved by the FDA for treatment of invasive aspergillosis in patients who fail to respond to or are unable to tolerate other antifungal drugs such as amphotericin B and itraconazole.
Med Lett Drugs Ther. 2001 Jul 9;43(1108):58-9 |  Show IntroductionHide Introduction

OTC Fluticasone Nasal Spray for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
infection (thrush), mucosal atrophy, and septal perforation have been reported rarely. Intranasal fungal ...
The nasal spray formulation of the corticosteroid fluticasone propionate is now available over the counter (OTC) as Flonase Allergy Relief (GSK) in the same strength as the prescription product (Flonase, and generics) for patients ≥4 years old with seasonal or perennial allergic rhinitis. It is the second corticosteroid nasal spray to become available OTC; triamcinolone acetonide (Nasacort Allergy 24HR) was the first. Unlike prescription Flonase, the OTC product is FDA-approved for reduction of ocular as well as nasal symptoms. Brand-name prescription Flonase has been...
Med Lett Drugs Ther. 2015 Mar 30;57(1465):48-9 |  Show IntroductionHide Introduction

Topical Sertaconazole (Ertaczo) -- Another Azole for Tinea Pedis

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004  (Issue 1185)
other imidazole antifungals, sertaconazole inhibits synthesis of ergosterol, an essential component of the fungal ...
Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis infection. It has been available in Europe for many years.
Med Lett Drugs Ther. 2004 Jun 21;46(1185):50-2 |  Show IntroductionHide Introduction

Cost of Topical Products for Tinea Pedis

   
The Medical Letter on Drugs and Therapeutics • May 03, 2010  (Issue 1337)
, an essential component of fungal cell membranes. Allylamines are more active in vitro than imidazoles against ...
A Medical Letter reader recently received a diagnosis of athlete’s foot and a prescription for Naftin gel, for which his pharmacy charged $145, and his insurance company required a $70 copay because this formulation was not included in its formulary. Do patients need to pay prices like these to treat tinea pedis?
Med Lett Drugs Ther. 2010 May 3;52(1337):35-6 |  Show IntroductionHide Introduction

Laser Treatment of Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2013  (Issue 1410)
. For further information call: 800-211-2769 Laser Treatment of Onychomycosis Fungal infections ...
Fungal infections of the fingernails or toenails can persist for months or years despite topical and systemic antimicrobial therapy. The FDA has cleared several short-pulse laser systems for treatment of this mainly cosmetic disorder.
Med Lett Drugs Ther. 2013 Feb 18;55(1410):15 |  Show IntroductionHide Introduction

Safe Needles

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Med Lett Drugs Ther. 1991 Apr 5;33(841):32 |  Show IntroductionHide Introduction

Omidubicel (Omisirge) for Neutrophil Recovery Following Myeloablative Conditioning Therapy (online only)

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
transplantation. Grade 2/3 bacterial or grade 3 invasive fungal infections up to 100 days post-transplantation ...
The FDA has approved omidubicel-onlv (Omisirge – Gamida Cell), a nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from cord blood, to reduce the time to neutrophil recovery and the risk of infection in patients ≥12 years old with hematologic malignancies who will undergo umbilical cord blood transplantation following myeloablative conditioning therapy. Hematopoietic progenitor cell (HPC) umbilical cord products (e.g., Allocord, Clevecord, Ducord) have been available in the US for years for the same indication. Cord blood banks also supply cord...
Med Lett Drugs Ther. 2023 May 29;65(1677):e93-4   doi:10.58347/tml.2023.1677h |  Show IntroductionHide Introduction

Golimumab (Simponi) for Inflammatory Arthritis

   
The Medical Letter on Drugs and Therapeutics • Jul 13, 2009  (Issue 1316)
fungal infections, and other opportunistic infections. The FDA has reported that invasive fungal ...
Golimumab (Simponi - Centocor), a fully humanized anti-tumor necrosis factor (TNF)-a antibody, has been approved by the FDA for the treatment of: (1) moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate; (2) active psoriatic arthritis (PsA) alone or in combination with methotrexate; and (3) active ankylosing spondylitis (AS).
Med Lett Drugs Ther. 2009 Jul 13;51(1316):55-6 |  Show IntroductionHide Introduction

Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
, oteseconazole inhibits the fungal sterol 14α- demethylase (CYP51). This enzyme catalyzes an early step ...
The FDA has approved oteseconazole (Vivjoa – Mycovia), a new oral azole antifungal, to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC. Oteseconazole is the first drug to be approved in the US specifically for treatment of RVVC.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):124-6 |  Show IntroductionHide Introduction

Rezafungin (Rezzayo) for Invasive Candida Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
infections. INVASIVE CANDIDA INFECTIONS ― Candida spp. are the most frequent cause of fungal diseases ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4   doi:10.58347/tml.2024.1705d |  Show IntroductionHide Introduction